About BOS complex subunit NOMO1
BOS complex subunit NOMO1 (NOMO1) is a protein
from Homo sapiens identified by UniProt accession
Q15155, 1222 residues long.
MolForge cross-references it against 0 known binders and
27 disease associations.
Target properties
| Protein name | BOS complex subunit NOMO1 |
|---|
| UniProt accession | Q15155 |
|---|
| Gene | NOMO1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 1222 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (27)
Diseases linked to this target (Open Targets).
- self reported educational attainment · score 0.08
- type 2 diabetes mellitus · score 0.07
- schizophrenia · score 0.04
- intelligence · score 0.04
- neoplasm · score 0.04
- sex hormone-binding globulin measurement · score 0.03
- reticulocyte measurement · score 0.03
- high density lipoprotein cholesterol measurement · score 0.02
- acute myeloid leukemia · score 0.02
- metabolic syndrome · score 0.02
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q15155-F1 | alphafold | PREDICTED | 81.22 | — |
Amino-acid sequence (1222 residues)
MLVGQGAGPL GPAVVTAAVV LLLSGVGPAH GSEDIVVGCG GFVKSDVEIN YSLIEIKLYT KHGTLKYQTD CAPNNGYFMI PLYDKGDFIL KIEPPLGWSF EPTTVELHVD GVSDICTKGG DINFVFTGFS VNGKVLSKGQ PLGPAGVQVS LRNTGTEAKI QSTVTQPGGK FAFFKVLPGD YEILATHPTW ALKEASTTVR VTNSNANAAS PLIVAGYNVS GSVRSDGEPM KGVKFLLFSS LVTKEDVLGC NVSPVPGFQP QDESLVYLCY TVSREDGSFS FYSLPSGGYT VIPFYRGERI TFDVAPSRLD FTVEHDSLKI EPVFHVMGFS VTGRVLNGPE GDGVPEAVVT LNNQIKVKTK ADGSFRLENI TTGTYTIHAQ KEHLYFETVT IKIAPNTPQL ADIIATGFSV CGQISIIRFP DTVKQMNKYK VVLSSQDKDK SLVTVETDAH GSFCFKAKPG TYKVQVMVPE AETRAGLTLK PQTFPLTVTN RPMMDVAFVQ FLASVSGKVS CLDTCGDLLV TLQSLSRQGE KRSLQLSGKV NAMTFTFDNV LPGKYKISIM HEDWCWKNKS LEVEVLEDDM SAVEFRQTGY MLRCSLSHAI TLEFYQDGNG RENVGIYNLS KGVNRFCLSK PGVYKVTPRS CHRFEQAFYT YDTSSPSILT LTAIRHHVLG TITTDKMMDV TVTIKSSIDS EPALVLGPLK SVQELRREQQ LAEIEARRQE REKNGNEEGE ERMTKPPVQE MVDELQGPFS YDFSYWARSG EKITVTPSSK ELLFYPPSME AVVSGESCPG KLIEIHGKAG LFLEGQIHPE LEGVEIVISE KGASSPLITV FTDDKGAYSV GPLHSDLEYT VTSQKEGYVL TAVEGTIGDF KAYALAGVSF EIKAEDDQPL PGVLLSLSGG LFRSNLLTQD NGILTFSNLS PGQYYFKPMM KEFRFEPSSQ MIEVQEGQNL KITITGYRTA YSCYGTVSSL NGEPEQGVAM EAVGQNDCSI YGEDTVTDEE GKFRLRGLLP GCVYHVQLKA EGNDHIERAL PHHRVIEVGN NDIDDVNIIV FRQINQFDLS GNVITSSEYL PTLWVKLYKS ENLDNPIQTV SLGQSLFFHF PPLLRDGENY VVLLDSTLPR SQYDYILPQV SFTAVGYHKH ITLIFNPTRK LPEQDIAQGS YIALPLTLLV LLAGYNHDKL IPLLLQLTSR LQGVRALGQA ASDNSGPEDA KRQAKKQKTR RT
Explore BOS complex subunit NOMO1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets